GlassScriptPhysician profile
Alexander Afanasyev
NPI 1972505030
$9,551.82
in general payments reported to CMS, 2019-2025
36 companies · $2,072 in 2025
The $2,072 reported for 2025 was more than what 89% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $946 · 2020: $902 · 2021: $925 · 2022: $1,182 · 2023: $1,265 · 2024: $2,260 · 2025: $2,072.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,581 · Education: $14.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,581.43 |
| Education | $14.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $1,180.58 | 2019-2025 | Veltassa, Korsuva |
| Astrazeneca Pharmaceuticals LP | $1,157.39 | 2019-2025 | Farxiga, Lokelma |
| Amgen INC. | $1,087.84 | 2019-2025 | Tavneos, Krystexxa, Aranesp |
| Otsuka America Pharmaceutical, INC. | $823.98 | 2019-2025 | Jynarque, Voyxact |
| Travere Therapeutics, INC. | $716.12 | 2022-2025 | |
| Fresenius USA Marketing, INC. | $677.39 | 2019-2025 | Velphoro, Velphoro |
| Alexion Pharmaceuticals, INC. | $510.42 | 2019-2024 | Ultomiris |
| Mallinckrodt Hospital Products INC. | $407.36 | 2021-2025 | Acthar, Terlivaz |
| Bayer Healthcare Pharmaceuticals INC. | $406.15 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $318.08 | 2022-2025 | |
| Opko Pharmaceuticals, LLC | $302.51 | 2019-2024 | Rayaldee |
| Boehringer Ingelheim Pharmaceuticals, INC. | $263.03 | 2022-2025 | Jardiance |
| Ardelyx, INC. | $203.37 | 2023-2025 | Ibsrela |
| Nxstage Medical, INC. | $200.54 | 2019-2025 | Nxstage System One, Liberty Select Cycler |
| Horizon Therapeutics Plc | $167.44 | 2019-2023 | Krystexxa, Procysbi |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $139.16 | 2024 | Cardiomems |
| Glaxosmithkline, LLC. | $131.41 | 2022-2025 | Benlysta, Jesduvroq, Arexvy |
| Akebia Therapeutics INC | $114.61 | 2019-2022 | |
| Eisai INC. | $84.35 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $74.50 | 2022-2023 | Gattex |
| Calliditas Therapeutics US INC. | $70.36 | 2024-2025 | Tarpeyo |
| Aurinia Pharma U.S., INC. | $69.22 | 2021-2025 | Lupkynis |
| Novo Nordisk INC | $61.78 | 2024-2025 | Ozempic, Rybelsus |
| Alnylam Pharmaceuticals INC. | $50.64 | 2025 | Givlaari, Oxlumo |
| Daiichi Sankyo INC. | $41.81 | 2019 | |
| Mallinckrodt Enterprises LLC | $41.31 | 2019 | |
| Genentech USA, INC. | $37.32 | 2019-2025 | Gazyva |
| Invivyd INC | $33.12 | 2024 | Pemgarda |
| Genzyme Corporation | $29.26 | 2024 | |
| Apellis Pharmaceuticals, INC. | $28.94 | 2025 | Empaveli |
| Lilly USA, LLC | $28.69 | 2023-2024 | Jardiance |
| Ultragenyx Pharmaceutical INC. | $28.53 | 2020-2023 | |
| Recordati_rare_diseases_inc. | $21.18 | 2023 | Panhematin |
| Shield Therapeutics INC | $18.49 | 2024 | |
| Leadiant Biosciences, INC. | $13.34 | 2020 | |
| Janssen Pharmaceuticals, INC | $11.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Afanasyev listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.